Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by SelfMadeon Mar 22, 2019 8:28am

70 Views

Post# 29521654

RE:RE:RE:RE:RE:RE:NEWS!!! “Excellent Results!!

No Jack4000 I believe that’s a fair analysis, good job buddy. It would be exclusive to us because in the GVHD treatment mkt right now, the best treatment option we’ve seen to date has a 15% success rate. Now if you compare that to the results we’ve had under a LOW dose (75 mg) 90%, then I would be quite confident in saying we would own the market under a 75 mg dose let alone once the results from a 150-300mg dose come in. Slam dunk is what I would call it.

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle